MHRA issues drug safety warning over ACE inhibitor side effect A drug safety warning has advised clinicians that ACE inhibitors should be halted immediately if a patient is suspected of presenting with angioedema during treatment.…
Regulator investigating pharmacists following report on gender prescribing at GP practice Exclusive: The General Pharmaceutical Council said it opened its investigation after a report revealed how “potential harm” had been caused to 78 children and young people seeking support for gender dysphoria or incongruence.…
GPhC chair among pharmacists celebrated in King’s Birthday Honours Gisela Abbam, chair of the General Pharmaceutical Council, has been recognised for her services to pharmacy.…
MHRA approves semaglutide oral tablets for weight loss The Medicines and Healthcare products Regulatory Agency advises that patients must start at the lowest 1.5mg daily dose of oral semaglutide tablets, which can be further increased to 4mg, 9mg and 25mg doses.…
The Critical Medicines Act: can the UK manage supply problems with the EU’s ‘safety belt’? Pharmacy leaders are hopeful that the Critical Medicines Act will help to alleviate medicines shortages in the UK, which have been rumbling on for several years.…
Kathie Cashell: ‘You can’t protect the public without an empowered profession’ As fitness-to-practise complaints to the General Pharmaceutical Council hit record highs, we spoke to new chief executive Kathie Cashell about her priorities for the organisation and the improvements she wants to deliver.…
Regulator vows to prioritise racism review recommendations General Pharmaceutical Council chief executive, Kathie Cashell, said “urgent, demonstrable and visible action is needed by all leaders”, following the publication of the Mann review.…
Blood pressure medication recalled after blister pack error A class two recall notice has advised healthcare professionals to immediately stop supplying the affected batch of ramipril 2.5mg capsules and quarantine all remaining stock.…
CPE committee minutes reveal concerns over proposed regulatory changes following Jhoots failures Members of a Community Pharmacy England committee said regulatory changes should not be made until it is made clear that they were “needed and would address the issues”.…
MHRA asks for views on rare disease therapy plans The ‘Rare disease therapies regulatory framework’ would incorporate a compressed regulatory pathway, aimed to reduce the cost of developing rare disease therapies and make them more affordable, the MHRA said.…
